Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Health-care companies fell as traders retreated from some of the highest risk issues.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

European shares were flat on Monday as investors took a breather after a week of high volatility due to uncertainties around ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...